Special Issue "IECC2022: Tumor Microenvironment Heterogeneity in Cancer Progression: Challenge or Opportunity"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 August 2022 | Viewed by 1251

Special Issue Editors

Prof. Dr. Samuel C. Mok
E-Mail Website
Guest Editor
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: gynecologic cancers; tumor microenvironment; diagnostic and prognostic biomarkers discovery; stomal-epithelial interaction; exosomes
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Paola Cappello
E-Mail Website
Guest Editor
Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy
Interests: pancreatic tumor; identification of antigens as diagnostic markers and potential immunotherapeutic targets; DNA vaccination; inflammation and fibrosis
Special Issues, Collections and Topics in MDPI journals
Dr. Sammy Ferri-Borgogno
E-Mail Website
Guest Editor
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: gynecologic oncology; reproductive medicine

Special Issue Information

Dear colleagues,

This Special Issue will comprise selected papers from the proceedings of the 2nd International Electronic Conference on Cancers: Tumor Microenvironment Heterogeneity in Cancer Progression: Challenge or Opportunity (IECC 2022) 14–16 February 2022, held on sciforum.net, an online platform for hosting scholarly e-conferences and discussion groups.

The focus of this conference is the translation of basic science understanding the tumor microenvironment and its dysregulation in cancer to its therapeutic exploitation, and is divided into twelve sessions, each with an invited keynote speaker and chair and short proffered talks on the following:

  • Tumor Heterogeneity and Chemoresistance
  • Tumor Heterogeneity and Immune Evasion
  • Clonal Evolution and Tumor Heterogeneity
  • Technological Platforms for Tumor and TME Heterogeneity Studies
  • Novel Computational Approaches in Tumor Analyses
  • Proteomics and Metabolomics to Dissect Tumor Tissue Heterogeneity
  • Targeting Tumor Microenvironment as Therapeutical Strategy to Hit Cancer: News from the Lab
  • Pre-Clinical Models to Study Cancer Heterogeneity: Emerging Technologies
  • Immunotherapy: Strategies to Unleash the Anti-Tumor Response

Selected papers that attract the most interest on the web or that provide a particularly innovative contribution will be selected for publication. These papers will be subjected to peer review and published with the aim of rapid and wide dissemination of research results, developments, and applications. We hope that this Conference Series will continue to grow in acceptance and recognition among potential participants, contributors, experts who want to disseminate their latest findings, and readers who seek information on tumor microenvironment heterogeneity in cancer progression.

Prof. Dr. Samuel Mok
Prof. Dr. Paola Cappello
Dr. Sammy Ferri-Borgogno
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia
Cancers 2022, 14(7), 1715; https://doi.org/10.3390/cancers14071715 - 28 Mar 2022
Viewed by 545
Abstract
Chimeric antigen receptor T cells (CAR T cells) have resulted in dramatic treatment responses for patients with hematologic malignancies, resulting in improved survival for patients with intractable disease. The first patient treated with CD19 directed CAR T cell therapy had chronic lymphocytic leukemia [...] Read more.
Chimeric antigen receptor T cells (CAR T cells) have resulted in dramatic treatment responses for patients with hematologic malignancies, resulting in improved survival for patients with intractable disease. The first patient treated with CD19 directed CAR T cell therapy had chronic lymphocytic leukemia (CLL) and achieved a complete remission. Subsequent clinical trials have focused largely on patients with other B-cell hematologic malignancies, owing to the fact that CAR T cell therapy for patients with CLL has met with challenges. More recent clinical trials have demonstrated CAR T cell therapy can be well tolerated and effective for patients with CLL, making it a potential treatment option for patients with this disease. In this article we review the background on CAR T cells for the treatment of patients with CLL, focusing on the unique obstacles that patients with CLL present for the development of adoptive T cell therapy, and the novel approaches currently under development to overcome these hurdles. Full article
Show Figures

Figure 1

Back to TopTop